358 related articles for article (PubMed ID: 14992907)
21. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
[TBL] [Abstract][Full Text] [Related]
22. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
Cugno M; Mari D; Meroni PL; Gronda E; Vicari F; Frigerio M; Coppola R; Bottasso B; Borghi MO; Gregorini L
Br J Haematol; 2004 Jul; 126(1):85-92. PubMed ID: 15198737
[TBL] [Abstract][Full Text] [Related]
23. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
24. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
[TBL] [Abstract][Full Text] [Related]
25. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
Tabuchi N; de Haan J; Boonstra PW; van Oeveren W
J Thorac Cardiovasc Surg; 1993 Nov; 106(5):828-33. PubMed ID: 8231204
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits).
Hazama S; Eishi K; Yamachika S; Noguchi M; Ariyoshi T; Takai H; Odate T; Matsukuma S; Onohara D; Yanatori M
Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):90-6. PubMed ID: 15209550
[TBL] [Abstract][Full Text] [Related]
28. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
Kruithof EK; Mestries JC; Gascon MP; Ythier A
Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
[TBL] [Abstract][Full Text] [Related]
29. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
[TBL] [Abstract][Full Text] [Related]
30. Hemostasis activation during esophageal variceal sclerotherapy with thrombin in cirrhotics.
Fujii Y; Sugawa C; Ozawa T; Nakumura R; Brown-Castillo J; Mammen EF
Am Surg; 1991 Apr; 57(4):222-5. PubMed ID: 1711300
[TBL] [Abstract][Full Text] [Related]
31. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
32. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
[TBL] [Abstract][Full Text] [Related]
33. Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses.
Paparella D; Semeraro F; Scrascia G; Galeone A; Ammollo CT; Kounakis G; de Luca Tupputi Schinosa L; Semeraro N; Colucci M
Ann Thorac Surg; 2010 Feb; 89(2):421-7. PubMed ID: 20103314
[TBL] [Abstract][Full Text] [Related]
34. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
Chandler WL; Velan T
Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
[TBL] [Abstract][Full Text] [Related]
35. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
[TBL] [Abstract][Full Text] [Related]
36. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
[TBL] [Abstract][Full Text] [Related]
37. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
38. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
39. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.
Spiess BD; Vocelka C; Cochran RP; Soltow L; Chandler WL
J Cardiothorac Vasc Anesth; 1998 Jun; 12(3):299-304. PubMed ID: 9636912
[TBL] [Abstract][Full Text] [Related]
40. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer.
Nanninga PB; van Teunenbroek A; Veenhof CH; Büller HR; ten Cate JW
Thromb Haemost; 1990 Nov; 64(3):361-4. PubMed ID: 1710832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
